Latest Hydantoins Stories
WOODCLIFF LAKE, N.J., Oct. 20, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S.
Researchers have identified genetic variants that are associated with severe adverse skin reactions to the antiepileptic drug phenytoin.
FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc.
Tokyo, Jan 16, 2012 - (JCN Newswire) - Nobelpharma Co. Ltd and Eisai Co.
NEW YORK, Oct. 11 /PRNewswire/ -- Attorney Keith Jensen of the Fort Worth, Texas-based law firm of Jensen, Belew & Gonzalez is announcing a $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc.
LOUISVILLE, Ky., July 6 /PRNewswire/ -- US WorldMeds is proud to announce the launch of Revonto(TM) (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH).
Phenytoin is a well known antiepileptic agent widely used throughout the world.